Akarsu H, Iwatsuki-Horimoto K, Noda T, Kawakami E, Katsura H, Baudin F, Horimoto T and Kawaoka Y (2011). Structure-based design of NS2 mutants for attenuated influenza A virus vaccines. Virus Research 155: 240–248.
Alexander DJ and Brown IH (2000). Recent zoonoses caused by influenza A viruses. Revue Scientifique et Technique 19: 197–225.
Babiuk S, Masic A, Graham J, Neufeld J, van der Loop M, Copps J, Berhane Y, Pasick J, Potter A, Babiuk LA, Weingartl H and Zhou Y (2011). An elastase-dependent attenuated heterologous swine influenza virus protects against pandemic H1N1 2009 influenza challenge in swine. Vaccine 29: 3118–3123.
Bachrach HL (1982). Recombinant DNA technology for the preparation of subunit vaccines. Journal of the American Veterinary Medical Association 181: 992–999.
Backstrom WE, Abdurahman S, Tranell A, Lindstrom S, Tingsborg S and Schwartz S (2011). Inefficient splicing of segment 7 and 8 mRNAs is an inherent property of influenza virus A/Brevig Mission/1918/1 (H1N1) that causes elevated expression of NS1 protein. Virology 422: 46–58.
Baltimore D, Huang AS and Stampfer M (1970). Ribonucleic acid synthesis of vesicular stomatitis virus, II. An RNA polymerase in the virion. Proceedings of the National Academy of Sciences of the United States of America 66: 572–576.
Belshe RB (2004). Current status of live attenuated influenza virus vaccine in the US. Virus Research 103: 177–185.
Bosworth B, Erdman MM, Stine DL, Harris I, Irwin C, Jens M, Loynachan A, Kamrud K and Harris DL (2010). Replicon particle vaccine protects swine against influenza. Comparative Immunology, Microbiology and Infectious Diseases 33: e99–e103.
Bouvier NM and Palese P (2008). The biology of influenza viruses. Vaccine 26 (Suppl 4): D49–53.
Braucher DR, Henningson JN, Loving CL, Vincent AL, Kim E, Steitz J, Gambotto AA and Kehrli ME Jr, (2012). Intranasal vaccination with replication-defective adenovirus type 5 encoding influenza virus hemagglutinin elicits protective immunity to homologous challenge and partial protection to heterologous challenge in pigs. Clinical and Vaccine Immunology 19: 1722–1729.
Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G and Ross TM (2007). Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25: 3871–3878.
Brown IH (2000). The epidemiology and evolution of influenza viruses in pigs. Veterinary Microbiology 74: 29–46.
Brown IH, Harris PA, McCauley JW and Alexander DJ (1998). Multiple genetic reassortment of avian and human influenza A viruses in European pigs, resulting in the emergence of an H1N2 virus of novel genotype. Journal of General Virology 79: 2947–2955.
Chan W, Zhou H, Kemble G and Jin H (2008). The cold adapted and temperature sensitive influenza A/Ann Arbor/6/60 virus, the master donor virus for live attenuated influenza vaccines, has multiple defects in replication at the restrictive temperature. Virology 380: 304–311.
Charley B, Riffault S and Van Reeth K (2006). Porcine innate and adaptative immune responses to influenza and coronavirus infections. Impact of Emerging Zoonotic Diseases on Animal Health 1081: 130–136.
Choi YK, Goyal SM, Farnham MW and Joo HS (2002). Phylogenetic analysis of H1N2 isolates of influenza A virus from pigs in the United States. Virus Research 87: 173–179.
Conzelmann KK (1998). Nonsegmented negative-strand RNA viruses: genetics and manipulation of viral genomes. Annual Review of Genetics 32: 123–162.
Cox MM and Hollister JR (2009). FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals: Journal of the International Association of Biological Standardization 37: 182–189.
Cox RJ, Brokstad KA and Ogra P (2004). Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scandinavian Journal of Immunology 59: 1–15.
D'Aoust MA, Lavoie PO, Couture MM, Trepanier S, Guay JM, Dargis M, Mongrand S, Landry N, Ward BJ and Vezina LP (2008). Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnology Journal 6: 930–940.
Dhama K, Mahendran M, Gupta PK and Rai A (2008). DNA vaccines and their applications in veterinary practice: current perspectives. Veterinary Research Communications 32: 341–356.
Dickerma RW, Baker GJ, Ordonez JV and Scherer WF (1973). Venezuelan equine encephalomyelitis viremia and antibody-responses of pigs and cattle. American Journal of Veterinary Research 34: 357–361.
Domingo E, Baranowski E, Ruiz-Jarabo CM, Martin-Hernandez AM, Saiz JC and Escarmis C (1998). Quasispecies structure and persistence of RNA viruses. Emerging Infectious Diseases 4: 521–527.
Draayer HA (2004). Autogenous vaccines: determining product need and antigen selection, production and testing considerations. Developments in Biologicals 117: 43–47.
Easterday BC and Van Reeth K (1999). Swine influenza. In: Straw BE, D'Allaire S, Mengling WL and Taylor DJ (eds) Diseases of Swine, 8th edn. Ames, IA: ISU Press, pp. 277–290.
Ellis J, Clark E, Haines D, West K, Krakowka S, Kennedy S and Allan GM (2004). Porcine circovirus-2 and concurrent infections in the field. Veterinary Microbiology 98: 159–163.
Erdman MM, Kamrud KI, Harris DL and Smith J (2010). Alphavirus replicon particle vaccines developed for use in humans induce high levels of antibodies to influenza virus hemagglutinin in swine: proof of concept. Vaccine 28: 594–596.
Fablet C, Marois-Crehan C, Simon G, Grasland B, Jestin A, Kobisch M, Madec F and Rose N (2012). Infectious agents associated with respiratory diseases in 125 farrow-to-finish pig herds: a cross-sectional study. Veterinary Microbiology 157: 152–163.
Foley PL (2001). Vaccine against swine influenza virus. U.S. Patent No. 6287570. Huxley, IA.
Gabriel G, Garn H, Wegmann M, Renz H, Herwig A, Klenk HD and Stech J (2008). The potential of a protease activation mutant of a highly pathogenic avian influenza virus for a pandemic live vaccine. Vaccine 26: 956–965.
Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions WM, Xu X, Skepner E, Deyde V, Okomo-Adhiambo M, Gubareva L, Barnes J, Smith CB, Emery SL, Hillman MJ, Rivailler P, Smagala J, Graaf MD, Burke DF, Fouchier RAM, Pappas C, Alpuche-Aranda CM, López-Gatell H, Olivera H, López I, Myers CA, Faix D, Blair PJ, Yu C, Keene KM, Dotson PD Jr., Boxrud D, Sambol AR, Abid SH, George KS, Bannerman T, Moore AL, Stringer DJ, Blevins P, Demmler-Harrison GJ, Ginsberg M, Kriner P, Waterman S, Smole S, Guevara HF, Belongia EA, Clark PA, Beatrice ST, Donis R, Katz J, Finelli L, Bridges CB, Shaw M, Jernigan DB, Uyeki TM, Smith DJ, Klimov AI and Cox NJ. (2009). Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325: 197–201.
Gauger PC and Vincent AL (2012). Swine influenza virus: epidemiology and vaccine concerns. In: Proceedings of the 19th Annual Swine Disease Conference for Swine Practitioners, November 10–11, 2011, Ames, Iowa, pp. 13–21.
Gauger PC, Vincent AL, Loving CL, Lager KM, Janke BH, Kehrli ME and Roth JA (2011). Enhanced pneumonia and disease in pigs vaccinated with an inactivated human-like (delta-cluster) H1N2 vaccine and challenged with pandemic 2009 H1N1 influenza virus. Vaccine 29: 2712–2719.
Gorres JP, Lager KM, Kong WP, Royals M, Todd JP, Vincent AL, Wei CJ, Loving CL, Zanella EL, Janke B, Kehrli ME, Nabel GJ and Rao SS (2011). DNA vaccination elicits protective immune responses against pandemic and classic swine influenza viruses in pigs. Clinical and Vaccine Immunology 18: 1987–1995.
Gramer MR, Lee JH, Choi YK, Goyal SM and Joo HS (2007). Serologic and genetic characterization of North American H3N2 swine influenza A viruses. Canadian Journal of Veterinary Research (Revue Canadienne De Recherche Veterinaire) 71: 201–206.
Grienke U, Schmidtke M, von Grafenstein S, Kirchmair J, Liedl KR and Rollinger JM (2012). Influenza neuraminidase: a druggable target for natural products. Natural Product Reports 29: 11–36.
Hale BG, Randall RE, Ortin J and Jackson D (2008). The multifunctional NS1 protein of influenza A viruses. Journal of General Virology 89: 2359–2376.
Harkness JW, Schild GC, Lamont PH and Brand CM (1972). Studies on relationships between human and porcine influenza 0.1. Serological evidence of infection in swine in Great Britain with an influenza A virus antigenically like human Hong Kong/68 virus. Bulletin of the World Health Organization 46: 709–719.
Hause BM, Oleson TA, Bey RF, Stine DL and Simonson RR (2010). Antigenic categorization of contemporary H3N2 swine influenza virus isolates using a high-throughput serum neutralization assay. Journal of Veterinary Diagnostic Investigation 22: 352–359.
Heinen PP, Van Nieuwstadt AP, de Boer-Luijtze EA and Bianchi ATJ (2001). Analysis of the quality of protection induced by a porcine influenza A vaccine to challenge with an H3N2 virus. Veterinary Immunology and Immunopathology 82: 39–56.
Hjulsager CK, Bragstad K, Bøtner A, Nielsen EO, Vigre H, Enøe C and Larsen LE (2006). New swine influenza A H1N2 reassortment found in Danish swine. In: Proceedings of the 19th IPVS Congress, July 16–19, 2006, Copenhagen, Denmark, Vol. 1, p. 265.
Karasin AI, Brown IH, Carman S and Olsen CW (2000). Isolation and characterization of H4N6 avian influenza viruses from pigs with pneumonia in Canada. Journal of Virology 74: 9322–9327.
Kida H, Ito T, Yasuda J, Shimizu Y, Itakura C, Shortridge KF, Kawaoka Y and Webster RG (1994). Potential for transmission of avian influenza-viruses to pigs. Journal of General Virology 75: 2183–2188.
Kitikoon P, Nilubol D, Erickson BJ, Janke BH, Hoover TC, Sornsen SA and Thacker EL (2006). The immune response and maternal antibody interference to a heterologous H1N1 swine influenza virus infection following vaccination. Veterinary Immunology and Immunopathology 112: 117–128.
Kitikoon P, Vincent AL, Gauger PC, Schlink SN, Bayles DO, Gramer MR, Darnell D, Webby RJ, Lager KM, Swenson SL and Klimov A (2012). Pathogenicity and transmission in pigs of the novel A(H3N2)v influenza virus isolated from humans and characterization of swine H3N2 viruses isolated in 2010–2011. Journal of Virology 86: 6804–6814.
Klumpp K, Ruigrok RW and Baudin F (1997). Roles of the influenza virus polymerase and nucleoprotein in forming a functional RNP structure. EMBO Journal 16: 1248–1257.
Klupp BG, Hengartner CJ, Mettenleiter TC and Enquist LW (2004). Complete, annotated sequence of the pseudorabies virus genome. Journal of Virology 78: 424–440.
Kumar SR, Deflube L, Biswas M, Shobana R and Elankumaran S (2011). Genetic characterization of swine influenza viruses (H3N2) isolated from Minnesota in 2006–2007. Virus Genes 43: 161–176.
Kyriakis CS, De Vleeschauwer A, Barbe F, Bublot M and Van Reeth K (2009). Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs. Vaccine 27: 2258–2264.
Landry N, Ward BJ, Trepanier S, Montomoli E, Dargis M, Lapini G and Vezina LP (2010). Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. Plos ONE 5: e15559.
Larsen DL and Olsen CW (2002). Effects of DNA dose, route of vaccination, and coadministration of porcine interleukin-6 DNA on results of DNA vaccination against influenza virus infection in pigs. American Journal of Veterinary Research 63: 653–659.
Larsen DL, Karasin A, Zuckermann F and Olsen CW (2000). Systemic and mucosal immune responses to H1N1 influenza virus infection in pigs. Veterinary Microbiology 74: 117–131.
Larsen DL, Karasin A and Olsen CW (2001). Immunization of pigs against influenza virus infection by DNA vaccine priming followed by killed-virus vaccine boosting. Vaccine 19: 2842–2853.
Lee JH, Gramer MR and Joo H (2007). Efficacy of swine influenza virus vacines against an H3N2 virus variant. Canadian Journal of Veterinary Research 71: 207–212.
Li GX, Zhou YJ, Yu H, Tian ZJ, Yan LP, Zhang Q, Hu SP and Tong GZ (2010). Prime-boost immunization with HA/C3d DNA followed by a recombinant pseudorabies virus boost enhanced protective immunity against H3N2 swine influenza virus in mice. Research in Veterinary Science 88: 345–351.
Lim YK, Takada A, Tanizaki T, Ozaki H, Okazaki K and Kida H (2001). Mucosal vaccination against influenza: protections of pigs immunized with inactivated virus and ether-split vaccine. Japanese Journal of Veterinary Research 48: 197–203.
Liu Q, Ma J, Liu H, Qi W, Anderson J, Henry SC, Hesse RA, Richt JA and Ma W (2012). Emergence of novel reassortant H3N2 swine influenza viruses with the 2009 pandemic H1N1 genes in the United States. Archives of Virology 157: 555–562.
Lorusso A, Vincent AL, Harland ML, Alt D, Bayles DO, Swenson SL, Gramer MR, Russell CA, Smith DJ, Lager KM and Lewis NS (2011). Genetic and antigenic characterization of H1 influenza viruses from United States swine from 2008. Journal of General Virology 92: 919–930.
Ma W and Richt JA (2010). Swine influenza vaccines: current status and future perspectives. Animal Health Research Reviews/Conference of Research Workers in Animal Diseases 11: 81–96.
Ma W, Vincent AL, Lager KM, Janke BH, Henry SC, Rowland RR, Hesse RA and Richt JA (2010). Identification and characterization of a highly virulent triple reassortant H1N1 swine influenza virus in the United States. Virus Genes 40: 28–36.
Ma W, Belisle SE, Mosier D, Li X, Stigger-Rosser E, Liu Q, Qiao C, Elder J, Webby R, Katze MG and Richt JA (2011). 2009 pandemic H1N1 influenza virus causes disease and upregulation of genes related to inflammatory and immune responses, cell death, and lipid metabolism in pigs. Journal of Virology 85: 11626–11637.
Macklin MD, McCabe D, McGregor MW, Neumann V, Meyer T, Callan R, Hinshaw VS and Swain WF (1998). Immunization of pigs with a particle-mediated DNA vaccine to influenza A virus protects against challenge with homologous virus. Journal of Virology 72: 1491–1496.
Maclachlan NJ and Dubovi EJ (2011). Chapter 21: Orthomyxoviridae. In: Maclachlan NJ and Dubovi EJ (eds) Fenner's Veterinary Virology, 4th edn. Saint Louis, MO: Academic Press, pp. 360–380.
Mahy BWJ (1997). Influenza A virus (FLUA). In Mahy BWJ (eds) A Dictionary of Virology, 2nd edn. San Diego, CA: Academic Press, pp. 170–171.
Markowska-Daniel I, Pomorska-Mol M and Pejsak Z (2011). The influence of age and maternal antibodies on the postvaccinal response against swine influenza viruses in pigs. Veterinary Immunology and Immunopathology 142: 81–86.
Masic A, Babiuk LA and Zhou Y (2009). Reverse genetics-generated elastase-dependent swine influenza viruses are attenuated in pigs. Journal of General Virology 90: 375–385.
Masic A, Lu X, Li J, Mutwiri GK, Babiuk LA, Brown EG and Zhou Y (2010). Immunogenicity and protective efficacy of an elastase-dependent live attenuated swine influenza virus vaccine administered intranasally in pigs. Vaccine 28: 7098–7108.
Matsuda M, Suizu F, Hirata N, Miyazaki T, Obuse C and Noguchi M (2010). Characterization of the interaction of influenza virus NS1 with Akt. Biochemical and Biophysical Research Communications 395: 312–317.
Moreno A, Di Trani L, Alborali L, Vaccari G, Barbieri I, Falcone E, Sozzi E, Puzelli S, Ferri G and Cordioli P (2010). First pandemic H1N1 outbreak from a pig farm in Italy. Open Virology Journal 4: 52–56.
Murphy FA, Gibbs EPJ, Horzinek MC and Studdert J (1999). Chapter 30: Orthomyxoviridae. In: Murphy FA, Gibbs EPJ, Horzinek MC and Studdert J (eds) Veterinary Virology, 3rd edn. San Diego, CA: Academic Press, pp. 459–468.
Myers T (2010). Subunit vaccine. In: Myers T (eds) Mosby's Medical Dictionary. Saint Louis, MO: Academic Press, pp. 1778.
Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM and Fiers W (1999). A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nature Medicine 5: 1157–1163.
Nelson MI, Vincent AL, Kitikoon P, Holmes EC and Gramer MR (2012). Evolution of novel reassortant A/H3N2 influenza viruses in North American swine and humans, 2009–2011. Journal of Virology 86: 8872–8878.
Nivitchanyong T, Yongkiettrakul S, Kramyu J, Pannengpetch S and Wanasen N (2011). Enhanced expression of secretable influenza virus neuraminidase in suspension mammalian cells by influenza virus nonstructural protein 1. Journal of Virological Methods 178: 44–51.
O'Neill RE, Talon J and Palese P (1998). The influenza virus NEP (NS2 protein) mediates the nuclear export of viral ribonucleoproteins. EMBO Journal 17: 288–296.
Olsen CW (2000). DNA vaccination against influenza viruses: a review with emphasis on equine and swine influenza. Veterinary Microbiology 74: 149–164.
Olsen CW, Karasin AI, Carman S, Li Y, Bastien N, Ojkic D, Alves D, Charbonneau G, Henning BM, Low DE, Burton L and Broukhanski G (2006). Triple reassortant H3N2 influenza A viruses, Canada, 2005. Emerging Infectious Diseases 12: 1132–1135.
Opriessnig T, Gimenez-Lirola LG and Halbur PG (2011). Polymicrobial respiratory disease in pigs. Animal Health Research Reviews/Conference of Research Workers in Animal Diseases 12: 133–148.
Paillot R, Hannant D, Kydd JH and Daly JM (2006). Vaccination against equine influenza: quid novi? Vaccine 24: 4047–4061.
Pandey A, Singh N, Vemula SV, Couetil L, Katz JM, Donis R, Sambhara S and Mittal SK (2012). Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine. Plos ONE 7: e33428.
Pensaert M, Labarque G, Favoreel H and Nauwynck H (2004). Aujeszky's disease vaccination and differentiation of vaccinated from infected pigs. Developments in Biologicals 119: 243–254.
Pertmer TM, Eisenbraun MD, McCabe D, Prayaga SK, Fuller DH and Haynes JR (1995). Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine 13: 1427–1430.
Platt R, Vincent AL, Gauger PC, Loving CL, Zanella EL, Lager KM, Kehrli ME Jr, Kimura K and Roth JA (2011). Comparison of humoral and cellular immune responses to inactivated swine influenza virus vaccine in weaned pigs. Veterinary Immunology and Immunopathology 142: 252–257.
Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE and Smith JF (1997). Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239: 389–401.
Rapp-Gabrielson VJ, Sornsen S, Nitzel G, Wicklund E, Wood MD, Kuhn M and Gramer M (2008). Updating swine influenza vaccines. In: AASV 39th Annual Meeting Proceedings, March 8–11, 2008, San Diego, CA, pp. 261–264.
Rayner JO, Dryga SA and Kamrud KI (2002). Alphavirus vectors and vaccination. Reviews in Medical Virology 12: 279–296.
Richt JA, Lager KM, Janke BH, Woods RD, Webster RG and Webby RJ (2003). Pathogenic and antigenic properties of phylogenetically distinct reassortant H3N2 swine influenza viruses cocirculating in the United States. Journal of Clinical Microbiology 41: 3198–3205.
Richt JA, Lekcharoensuk P, Lager KM, Vincent AL, Loiacono CM, Janke BH, Wu WH, Yoon KJ, Webby RJ, Solorzano A and Garcia-Sastre A (2006). Vaccination of pigs against swine influenza viruses by using an NS1-truncated modified live-virus vaccine. Journal of Virology 80: 11009–11018.
Rimmelzwaan GF and Sutter G (2009). Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara. Expert Review of Vaccines 8: 447–454.
Romagosa A, Allerson M, Gramer M, Joo HS, Deen J, Detmer S and Torremorell M (2011). Vaccination of influenza a virus decreases transmission rates in pigs. Veterinary Research 42: 120.
Shaw ML, Stone KL, Colangelo CM, Gulcicek EE and Palese P (2008). Cellular proteins in influenza virus particles. PLoS Pathogens 4: e1000085.
Shoji Y, Chichester JA, Jones M, Manceva SD, Damon E, Mett V, Musiychuk K, Bi H, Farrance C, Shamloul M, Kushnir N, Sharma S and Yusibov V (2011). Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza. Human Vaccines 7 (Suppl): 41–50.
Shope RE (1931). Swine influenza : III. Filtration experiments and etiology. Journal of Experimental Medicine 54: 373–385.
Skehel JJ and Wiley DC (2000). Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annual Review of Biochemistry 69: 531–569.
Smerdou C and Liljestrom P (1999). Two-helper RNA system for production of recombinant Semliki forest virus particles. Journal of Virology 73: 1092–1098.
Solorzano A, Webby RJ, Lager KM, Janke BH, Garcia-Sastre A and Richt JA (2005). Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs. Journal of Virology 79: 7535–7543.
Stech J, Garn H, Wegmann M, Wagner R and Klenk HD (2005). A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin. Nature Medicine 11: 683–689.
Talon J, Salvatore M, O'Neill RE, Nakaya Y, Zheng H, Muster T, Garcia-Sastre A and Palese P (2000). Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach. Proceedings of the National Academy of Sciences of the United States of America 97: 4309–4314.
Thacker EL, Thacker BJ and Janke BH (2001). Interaction between Mycoplasma hyopneumoniae and swine influenza virus. Journal of Clinical Microbiology 39: 2525–2530.
Thompson JM, Nicholson MG, Whitmore AC, Zamora M, West A, Iwasaki A, Staats HF and Johnston RE (2008). Nonmucosal alphavirus vaccination stimulates a mucosal inductive environment in the peripheral draining lymph node. Journal of Immunology 181: 574–585.
Tian ZJ, Zhou GH, Zheng BL, Qiu HJ, Ni JQ, Yang HL, Yin XN, Hu SP and Tong GZ (2006). A recombinant pseudorabies virus encoding the HA gene from H3N2 subtype swine influenza virus protects mice from virulent challenge. Veterinary Immunology and Immunopathology 111: 211–218.
Tong SX, Li Y, Rivailler P, Conrardy C, Castillo DAA, Chen LM, Recuenco S, Ellison JA, Davis CT, York IA, Turmelle AS, Moran D, Rogers S, Shi M, Tao Y, Weil MR, Tang K, Rowe LA, Sammons S, Xu XY, Frace M, Lindblade KA, Cox NJ, Anderson LJ, Rupprecht CE and Donis RO (2012). A distinct lineage of influenza A virus from bats. Proceedings of the National Academy of Sciences of the United States of America 109: 4269–4274.
Tremblay D, Allard V, Doyon JF, Bellehumeur C, Spearman JG, Harel J and Gagnon CA (2011). Emergence of a new swine H3N2 and pandemic (H1N1) 2009 influenza A virus reassortant in two Canadian animal populations, mink and swine. Journal of Clinical Microbiology 49: 4386–4390.
Vander Veen R, Kamrud K, Mogler M, Loynachan AT, McVicker J, Berglund P, Owens G, Timberlake S, Lewis W, Smith J and Harris DL (2009). Rapid development of an efficacious swine vaccine for novel H1N1. PLoS Currents 1: RRN1123.
Vander Veen RL (2011). Development of efficacious replicon particle vaccines for swine influenza virus. Graduate Theses and Dissertations Paper 10373. Available online at http://lib.dr.iastate.edu/etd/10373 (Accessed 29 June 2012).
Vander Veen RL, Harris DL and Kamrud KI (2012a). Alphavirus replicon vaccines. Animal Health Research Reviews 13: 1–9.
Vander Veen RL, Loynachan AT, Mogler MA, Russell BJ, Harris DL and Kamrud KI (2012b). Safety, immunogenicity, and efficacy of an alphavirus replicon-based swine influenza virus hemagglutinin vaccine. Vaccine 30: 1944–1950.
Van Reeth K (2000). Cytokines in the pathogenesis of influenza. Veterinary Microbiology 74: 109–116.
Verheust C, Goossens M, Pauwels K and Breyer D (2012). Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination. Vaccine 30: 2623–2632.
Vincent AL, Lager KM, Ma W, Lekcharoensuk P, Gramer MR, Loiacono C and Richt JA (2006). Evaluation of hemagglutinin subtype 1 swine influenza viruses from the United States. Veterinary Microbiology 118: 212–222.
Vincent AL, Ma W, Lager KM, Janke BH, Webby RJ, Garcia-Sastre A and Richt EA (2007). Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine. Vaccine 25: 7999–8009.
Vincent AL, Ma W, Lager KM, Janke BH and Richt JA (2008a). Swine influenza viruses: a North American perspective. Advances in Virus Research 72: 127–154.
Vincent AL, Lager KM, Janke BH, Gramer MR and Richt JA (2008b). Failure of protection and enhanced pneumonia with a US H1N2 swine influenza virus in pigs vaccinated with an inactivated classical swine H1N1 vaccine. Veterinary Microbiology 126: 310–323.
Vincent AL, Ma W, Lager KM, Gramer MR, Richt JA and Janke BH (2009). Characterization of a newly emerged genetic cluster of H1N1 and H1N2 swine influenza virus in the United States. Virus Genes 39: 176–185.
Vincent AL, Ciacci-Zanella JR, Lorusso A, Gauger PC, Zanella EL, Kehrli ME Jr, Janke BH and Lager KM (2010a). Efficacy of inactivated swine influenza virus vaccines against the 2009 A/H1N1 influenza virus in pigs. Vaccine 28: 2782–2787.
Vincent AL, Lager KM, Faaberg KS, Harland M, Zanella EL, Ciacci-Zanella JR, Kehrli ME Jr, Janke BH and Klimov A (2010b). Experimental inoculation of pigs with pandemic H1N1 2009 virus and HI cross-reactivity with contemporary swine influenza virus antisera. Influenza and Other Respiratory Viruses 4: 53–60.
Wang C, Takeuchi K, Pinto LH and Lamb RA (1993). Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. Journal of Virology 67: 5585–5594.
Webby RJ, Swenson SL, Krauss SL, Gerrish PJ, Goyal SM and Webster RG (2000). Evolution of swine H3N2 influenza viruses in the United States. Journal of Virology 74: 8243–8251.
Webby RJ, Rossow K, Erickson G, Sims Y and Webster R (2004). Multiple lineages of antigenically and genetically diverse influenza A virus co-circulate in the United States swine population. Virus Research 103: 67–73.
Webster RG (1999). 1918 Spanish influenza: the secrets remain elusive. Proceedings of the National Academy of Sciences of the United States of America 96: 1164–1166.
Wesley RD and Lager KM (2006). Overcoming maternal antibody interference by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of swine influenza virus. Veterinary Microbiology 118: 67–75.
Wesley RD, Tang M and Lager KM (2004). Protection of weaned pigs by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of H3N2 swine influenza virus. Vaccine 22: 3427–3434.
Wise HM, Foeglein A, Sun JC, Dalton RM, Patel S, Howard W, Anderson EC, Barclay WS and Digard P (2009). A complicated message: identification of a novel PB1-related protein translated from influenza A virus segment 2 mRNA. Journal of Virology 83: 8021–8031.
Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A and Felgner PL (1990). Direct gene transfer into mouse muscle in vivo. Science 247: 1465–1468.
Yuan Z, Zhang S, Liu Y, Zhang F, Fooks AR, Li Q and Hu R (2008). A recombinant pseudorabies virus expressing rabies virus glycoprotein: safety and immunogenicity in dogs. Vaccine 26: 1314–1321.
Zell R, Scholtissek C and Ludwig S (2012). Genetics, evolution, and the zoonotic capacity of European swine influenza viruses. Current Topics in Microbiology and Immunology (advance access published Sep 26, 2012), doi:10.1007/82_2012_267.
Zhao K, Shi X, Zhao Y, Wei H, Sun Q, Huang T, Zhang X and Wang Y (2011). Preparation and immunological effectiveness of a swine influenza DNA vaccine encapsulated in chitosan nanoparticles. Vaccine 29: 8549–8556.
Zhou NN, Senne DA, Landgraf JS, Swenson SL, Erickson G, Rossow K, Liu L, Yoon KJ, Krauss S and Webster RG (1999). Genetic reassortment of avian, swine, and human influenza A viruses in American pigs. Journal of Virology 73: 8851–8856.